Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
David Livingston, a giant in oncology research known for his significant contributions to translational cancer research, unexpectedly died. He was 80.
Parse Biosciences’ multiplexed approach enables 96 samples and a total of 1 million single cells to be analyzed in parallel without the need for specialized lab instruments.
Investors can take their pick of life sciences companies, with more innovative ideas and treatments being added to pipelines daily. Here’s who brought in the sheaves this week.
Although California is already a well-known hotbed for science and technology, the pandemic still precipitated a surge of activity in the life sciences industry.
Crinetics Pharmaceuticals, along with 5AM Ventures and Frazier Healthcare Partners, announced that it was spinning out a new company, Radionetics Oncology.
Redosing is a large and growing concern for gene therapy developers and regulators.
The Delta variant is the deadliest variant of the coronavirus, and according to the CDC, this variant has the highest transmission rate yet.
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.
June really broke out in 2012 when he saved the life of Emily Whitehead, a child suffering from relapsed acute lymphoblastic leukemia (ALL), with CD19 CAR-T.
With expectations that the U.S. FDA will announce a decision about booster shots for the Moderna and Johnson & Johnson vaccines this week, there is plenty of COVID-19-related news. Here’s a look.
The idea of using mRNA has been around for some time, but only in recent years has it become practical. The COVID-19 pandemic provided the opportunity for the technology to push ahead.
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.